Compare AbbVie Inc (ABBV) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck Junior Gold Miners — how do they compare? AbbVie Inc trades at $253.48 (market cap $449.91B), while VanEck Junior Gold Miners trades at $95.48. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck Junior Gold Miners pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ABBV | GDXJ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $156.19 |
52-Week Low | $184.85 | $64.22 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
GDXJ trades at $103.91, up 0.97% today, with technical indicators showing mixed signals (neutral overall, bearish moving averages). The ETF faces headwinds from underperformance versus peers in 2026, with significant portfolio overlap and limited small-cap exposure. Recent news highlights silver price volatility and gold's rally near $4,700, affecting junior miner sentiment.
The outlook remains cautious due to Federal Reserve rate uncertainty and competitive pressures. Investment opportunities hinge on gold price sustainability, but risks include sector underperformance and macroeconomic sensitivity. Analyst sentiment is neutral to bearish, reflecting concerns over the ETF's strategic positioning and recent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
